Abbott Laboratories (ABT) Other Non Operating Income (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Other Non Operating Income data on file, last reported at $159.0 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 2171.43% year-over-year to $159.0 million; the trailing twelve-month figure through Mar 2026 stood at $202.0 million (down 59.03% YoY), and the FY2025 full-year result was -$5.9 billion, up 20.97% from the prior year.
• Other Non Operating Income improved to $159.0 million in Q1 2026, from $15.0 million in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $359.0 million in Q4 2024 to a low of $6.0 million in Q2 2024.
• A 5-year average of $110.2 million and a median of $88.0 million in 2022 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income soared 2700.0% in 2022 and sank 96.59% in 2024, its largest moves.
• Tracing ABT's Other Non Operating Income over 5 years: stood at $337.0 million in 2022, then plunged by 67.66% to $109.0 million in 2023, then surged by 229.36% to $359.0 million in 2024, then slumped by 95.82% to $15.0 million in 2025, then soared by 960.0% to $159.0 million in 2026.
• Business Quant data shows ABT's Other Non Operating Income at $159.0 million in Q1 2026, $15.0 million in Q4 2025, and $17.0 million in Q3 2025.